Gabelli Funds LLC Has $15.53 Million Stake in Edwards Lifesciences Corp (EW)

Gabelli Funds LLC lifted its position in Edwards Lifesciences Corp (NYSE:EW) by 9.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 89,200 shares of the medical research company’s stock after purchasing an additional 7,600 shares during the period. Gabelli Funds LLC’s holdings in Edwards Lifesciences were worth $15,530,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Bank Hapoalim BM grew its stake in Edwards Lifesciences by 10.4% during the second quarter. Bank Hapoalim BM now owns 3,730 shares of the medical research company’s stock valued at $543,000 after acquiring an additional 350 shares in the last quarter. Janney Montgomery Scott LLC grew its stake in Edwards Lifesciences by 2.2% during the second quarter. Janney Montgomery Scott LLC now owns 16,336 shares of the medical research company’s stock valued at $2,378,000 after acquiring an additional 355 shares in the last quarter. Wendell David Associates Inc. grew its stake in Edwards Lifesciences by 4.0% during the second quarter. Wendell David Associates Inc. now owns 9,548 shares of the medical research company’s stock valued at $1,390,000 after acquiring an additional 363 shares in the last quarter. Park Avenue Securities LLC grew its stake in Edwards Lifesciences by 9.6% during the second quarter. Park Avenue Securities LLC now owns 4,411 shares of the medical research company’s stock valued at $645,000 after acquiring an additional 387 shares in the last quarter. Finally, Tyers Asset Management LLC grew its stake in Edwards Lifesciences by 6.1% during the second quarter. Tyers Asset Management LLC now owns 6,832 shares of the medical research company’s stock valued at $995,000 after acquiring an additional 392 shares in the last quarter. 82.71% of the stock is owned by hedge funds and other institutional investors.

Several equities analysts recently weighed in on EW shares. Zacks Investment Research raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research note on Saturday, July 14th. Northland Securities reaffirmed a “hold” rating and set a $120.00 target price on shares of Edwards Lifesciences in a research note on Friday, July 27th. Jefferies Financial Group reaffirmed a “buy” rating and set a $168.00 target price on shares of Edwards Lifesciences in a research note on Friday, July 27th. JPMorgan Chase & Co. raised their target price on shares of Edwards Lifesciences from $133.00 to $150.00 and gave the company a “neutral” rating in a research note on Friday, July 27th. Finally, Wells Fargo & Co increased their price objective on shares of Edwards Lifesciences from $152.00 to $170.00 and gave the company an “outperform” rating in a research report on Friday, July 27th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $156.79.

EW stock opened at $153.18 on Friday. Edwards Lifesciences Corp has a 52 week low of $103.20 and a 52 week high of $175.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.31 and a quick ratio of 1.85. The firm has a market cap of $33.00 billion, a price-to-earnings ratio of 35.31, a price-to-earnings-growth ratio of 2.08 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, October 23rd. The medical research company reported $1.07 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.02 by $0.05. Edwards Lifesciences had a net margin of 20.67% and a return on equity of 30.11%. The business had revenue of $906.60 million during the quarter, compared to analyst estimates of $927.56 million. During the same quarter last year, the business earned $0.84 earnings per share. Edwards Lifesciences’s quarterly revenue was up 10.4% compared to the same quarter last year. Research analysts anticipate that Edwards Lifesciences Corp will post 4.7 EPS for the current fiscal year.

In other news, VP Catherine M. Szyman sold 700 shares of the firm’s stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $142.64, for a total value of $99,848.00. Following the completion of the sale, the vice president now owns 27,772 shares in the company, valued at approximately $3,961,398.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Huimin Wang sold 33,800 shares of the firm’s stock in a transaction dated Tuesday, November 6th. The stock was sold at an average price of $150.43, for a total transaction of $5,084,534.00. Following the completion of the sale, the vice president now owns 81,665 shares of the company’s stock, valued at approximately $12,284,865.95. The disclosure for this sale can be found here. Insiders sold a total of 150,311 shares of company stock valued at $21,718,936 in the last 90 days. Company insiders own 1.84% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Gabelli Funds LLC Has $15.53 Million Stake in Edwards Lifesciences Corp (EW)” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/11/10/gabelli-funds-llc-has-15-53-million-stake-in-edwards-lifesciences-corp-ew.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Further Reading: How Do Tariffs Affect Trade Balances?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply